Skip to main content
🇺🇸 100% Domestic·Synthesized & Shipped in the USABuy 2+ Save 10%·Buy 3+ Save 15%·Buy 5+ Save 20%Free Shipping on Orders Over $200Ships in 24–48 Hours — 100% DomesticThird-Party Tested·COAs Available on RequestResearch Grade·≥ 99% Purity Standard🇺🇸 100% Domestic·Synthesized & Shipped in the USABuy 2+ Save 10%·Buy 3+ Save 15%·Buy 5+ Save 20%Free Shipping on Orders Over $200Ships in 24–48 Hours — 100% DomesticThird-Party Tested·COAs Available on RequestResearch Grade·≥ 99% Purity Standard
USA Synthesized & Shipped
Third-Party Lab Tested
≥99% Purity Guaranteed
Free US Shipping $200+
Growth Hormone Research · 6/26/2026 · 1 min read

CJC-1295 Expanded Research Guide 2026 — DAC vs Non-DAC, GHRH Mechanism & Stack Research

CJC-1295 exists in two structurally distinct forms — with and without Drug Affinity Complex — that produce dramatically different pharmacokinetic profiles and research applications. The distinction matters more than most researchers initially realize.

By Owen Loughran
ShareX / TwitterReddit
For research and laboratory use only. Not for human consumption, diagnosis, or treatment.

CJC-1295 is among the most frequently researched GHRH analogs in the catalog — and also among the most frequently confused, because two fundamentally different compounds share the same base name depending on whether the Drug Affinity Complex modification is present or absent.

CJC-1295 with DAC — Continuous Long-Duration Stimulation

The Drug Affinity Complex (DAC) modification enables CJC-1295 to covalently bind circulating albumin, which acts as a slow-release reservoir — continuously releasing active compound over days rather than hours. This produces a half-life measured in days, enabling once-weekly research dosing and a sustained, non-pulsatile GHRH receptor stimulation profile. Research sometimes describes the resulting continuous low-level GH elevation as a "GH bleed" — distinguishing it from the discrete pulsatile releases that shorter-acting secretagogues produce.

CJC-1295 without DAC — Short-Acting Pulsatile Profile

Without the DAC modification, CJC-1295 behaves more like the native GHRH fragment it's derived from — a short half-life producing a discrete GH pulse rather than sustained elevation. This form is pharmacokinetically closer to Sermorelin than to DAC-modified CJC-1295, despite the shared name. For researchers interested in mimicking physiologic pulsatile GH release patterns, the non-DAC form is the more relevant research tool.

GHRH Receptor Mechanism

Both forms activate the same GHRH receptor on pituitary somatotrophs — the same Gs-protein-coupled cascade that increases intracellular cAMP and triggers GH synthesis and secretion. The mechanistic difference is entirely pharmacokinetic: how long the receptor is occupied, not how it's activated.

Combination Research with Ipamorelin

CJC-1295's GHRH receptor mechanism is the GHRH-pathway component of the most studied GH-axis stack — paired with Ipamorelin's ghrelin receptor activation to produce dual-pathway GH pulse synergy. The full stack rationale is covered in our CJC-1295 + Ipamorelin stack guide.

Related Research CJC-1295 + Ipamorelin Stack Guide Tesamorelin vs CJC-1295 Comparison Ipamorelin Expanded Research Guide HGH Pulsatile Release Research

Research Use Only. DisclaimerFor laboratory and research use only. Not for human consumption. This content is educational and does not constitute medical advice.
For research and laboratory use only.
Related Research Articles
Community
Explore the Community

Neutral, moderated research discussion. Laboratory use only.

Research Library
Read More in the Library

More compound guides, hubs, and educational research materials.